Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.

Abstract:

BACKGROUND:Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. The objectives of this study are (1) to explore any trends in physician-dispensed drug prices; (2) to compare the proportion of drugs with and without a price and to determine the financial implications of repricing CAWCS physician-dispensed drugs with five alternative pricing benchmarks; and (3) to offer recommendations for the pricing benchmark to maximize pricing coverage and to remain budget neutral. METHODS:We evaluated physician-dispensed drugs at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported. We matched each claim line in the CAWCS to the corresponding unit price of an alternative price benchmark including average wholesale price, wholesale acquisition cost, direct prices, national average drug acquisition cost, and Federal Upper Limit. RESULTS:Average wholesale price provided prices for 99.9% of physician-dispensed drug claims, while Medi-Cal, the current primary physician-dispensed drug benchmark provided prices for a lower percentage (92.7%) of claims. The CAWCS prices were equivalent to 49% of the average wholesale price, 95.5% of Medi-Cal, 126.7% of the wholesale acquisition cost, 266% of the Federal Upper Limit, 64.4% of direct prices, and 197% of national average drug acquisition cost-estimated prices. CONCLUSIONS:The CAWCS current Medi-Cal pricing for physician-dispensed drugs is better than all alternatives in terms of price availability, transparency, and budget neutrality, but pricing availability may decrease over time as Medi-Cal moves to managed care. National average drug acquisition cost is the next best alternative, but it requires combinations of pricing benchmarks to maximize its price availability.

authors

Wilson L,Turkistani F,Tran DM,Huang W,Lin TK

doi

10.1007/s40258-018-0442-2

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

231-242

issue

2

eissn

1175-5652

issn

1179-1896

pii

10.1007/s40258-018-0442-2

journal_volume

17

pub_type

杂志文章
  • Health State Utility Values for Age-Related Macular Degeneration: Review and Advice.

    abstract::Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility values in AMD. We describe how utility values have been used in heal...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-016-0275-9

    authors: Butt T,Tufail A,Rubin G

    更新日期:2017-02-01 00:00:00

  • Healthcare payment incentives: a comparative analysis of reforms in Taiwan, South Korea and China.

    abstract::Payment incentives to both consumers and providers have significant consequences for the equity and efficiency of a healthcare system, and have recently come to the fore in health policy reforms. This review first discusses the economic rationale for the apparent international convergence toward payment systems with m...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200403010-00009

    authors: Eggleston K,Hsieh CR

    更新日期:2004-01-01 00:00:00

  • Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.

    abstract:BACKGROUND:In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. OBJECTIVE:The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the UK. METHODS:In the MONE...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11592220-000000000-00000

    authors: Gazzard B,Hill A,Anceau A

    更新日期:2011-07-01 00:00:00

  • Why does economic analysis in health care not get implemented more? Towards a greater understanding of the rules of the game and the costs of decision making.

    abstract::Despite recent initiatives across a number of countries to institutionalise the use of economic evaluation in the assessment of new technologies, the evidence suggests that, to date, the impact of economic analysis on health sector decision making in practice has been low. This paper proposes that incentive compatibil...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Jan S

    更新日期:2003-01-01 00:00:00

  • Socioeconomic Disparities in Unmet Need for Student Mental Health Services in Higher Education.

    abstract:BACKGROUND:Mental health problems are highly prevalent among college students in many countries. However, evidence suggests that many at-risk students do not receive professional help. OBJECTIVE:We aimed to understand which students are most likely to have unmet need for mental health services. Given increasing and wi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-019-00529-9

    authors: Cullinan J,Walsh S,Flannery D

    更新日期:2020-04-01 00:00:00

  • Curos™ Disinfection Caps for the Prevention of Infection When Using Needleless Connectors: A NICE Medical Technologies Guidance.

    abstract::Central line-associated bloodstream infections (CLABSIs) are primary, laboratory confirmed bloodstream infections in patients with a central line within 48 h of symptom onset. Catheter-related bloodstream infection (CRBSI) is a more specific term used when the cause of infection has been confirmed by catheter tip cult...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-020-00602-8

    authors: O'Connell S,Dale M,Morgan H,Carter K,Carolan-Rees G

    更新日期:2020-08-05 00:00:00

  • Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

    abstract:BACKGROUND:Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is known about the economic burden associated with PAH patients in the US. OBJECTIVES:The objective of this study was to estimate excess direct costs associated with privately insured PAH patients in the US. METHODS:From a privately ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11592430-000000000-00000

    authors: Kirson NY,Birnbaum HG,Ivanova JI,Waldman T,Joish V,Williamson T

    更新日期:2011-09-01 00:00:00

  • Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.

    abstract:BACKGROUND:It is estimated that annually 300 000 cases of rotavirus-induced gastroenteritis (RVGE) occur in children aged up to 5 years in France. A two-dose vaccine against rotavirus infection (RIX4414; Rotarix, GlaxoSmithKline), has been shown to be highly effective against severe RVGE. OBJECTIVE:This study evaluate...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256134

    authors: Standaert B,Parez N,Tehard B,Colin X,Detournay B

    更新日期:2008-01-01 00:00:00

  • Cost of Medicare for All: Review of the Estimates.

    abstract::This paper critically evaluates the estimates of the cost of Medicare for All (M4A) in the USA. Six studies that estimate the 1-year total cost of M4A in the USA are reviewed. These studies find that M4A would increase national health spending by as much as 16.9% or decrease it by 20.0%, representing a range of estima...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-021-00636-6

    authors: Nyman JA

    更新日期:2021-01-25 00:00:00

  • Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome.

    abstract:BACKGROUND:Response to growth hormone (GH) therapy may vary between individual patients. Therefore the use of GH in children should be closely monitored to avoid over, under, or ineffective treatment regimens. The treatment response can be evaluated using growth prediction models. In an effort to improve the accuracy o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0030-4

    authors: Kaspers S,Ranke MB,Han D,Loftus J,Wollmann H,Lindberg A,Roelants M,Kleintjens J

    更新日期:2013-06-01 00:00:00

  • Supplier-induced demand: reconsidering the theories and new Australian evidence.

    abstract::This paper reconsiders the evidence and several of the key arguments associated with the theory of supplier-induced demand (SID). It proposes a new theory to explain how ethical behaviour is consistent with SID. The purpose of a theory of demand and one criterion for the evaluation of a theory is the provision of a pl...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.2165/00148365-200605020-00003

    authors: Richardson JR,Peacock SJ

    更新日期:2006-01-01 00:00:00

  • The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Trial.

    abstract:BACKGROUND:Chronic obstructive pulmonary disease (COPD) affects approximately 3 million people in the UK. An 8-week pulmonary rehabilitation (PR) course is recommended under current guidelines. However, studies show that initial benefits diminish over time. OBJECTIVE:We present here an economic evaluation conducted al...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40258-015-0199-9

    authors: Burns DK,Wilson EC,Browne P,Olive S,Clark A,Galey P,Dix E,Woodhouse H,Robinson S,Wilson A

    更新日期:2016-02-01 00:00:00

  • Modelling the costs and outcomes of changing rates of screening for alcohol misuse by GPs in the Australian context.

    abstract:AIM:To assess the relative cost effectiveness of four strategies (academic detailing, computerised reminder systems, target payments and interactive continuing medical education) to increase the provision of screening and brief interventions by Australian GPs with the ultimate goal of decreasing risky alcohol consumpti...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200605030-00002

    authors: Shanahan M,Shakeshaft A,Mattick RP

    更新日期:2006-01-01 00:00:00

  • Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services.

    abstract:BACKGROUND:little is known about the economics of acquiring and processing the more than 14 million units of red blood cells used annually in the US. OBJECTIVE:to determine the average price paid by hospitals to suppliers for a unit of red blood cells and to identify cost variations by region and facility type and siz...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11530740-000000000-00000

    authors: Toner RW,Pizzi L,Leas B,Ballas SK,Quigley A,Goldfarb NI

    更新日期:2011-01-01 00:00:00

  • Listening to the decision makers: sustainability of PBMA in Alberta.

    abstract:BACKGROUND:Decision makers within the Calgary Health Region adopted and applied programme budgeting and marginal analysis (PBMA) for priority-setting activity across major service portfolios within the Region. METHODS:Seventeen in-depth qualitative interviews were conducted with senior managers and clinicians to gain ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200403030-00005

    authors: Mitton C,Patten S,Donaldson C

    更新日期:2004-01-01 00:00:00

  • Does Insurance Status Influence a Patient's Hospital Charge?

    abstract:BACKGROUND:There is obscurity regarding how US hospitals determine patients' charges. Whether insurance status influences a patient's hospital charge has not been explored. OBJECTIVE:The objective of this study was to determine whether hospitals charge patients differently based on their insurance status. METHODS:Thi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-017-0308-z

    authors: Woodworth L,Romano PS,Holmes JF

    更新日期:2017-06-01 00:00:00

  • New anti-rebate legislation in South Korea.

    abstract::The South Korean Government recently announced a reform in the drug anti-rebate law, with the purpose of eradicating pervasive, unethical, and illegal rebate practices in pharmaceutical marketing. The main objective of this reform is to have the ability to bring criminal charges against doctors and pharmacists for rec...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-013-0029-x

    authors: Yu SY,Yang BM,Kim JH

    更新日期:2013-08-01 00:00:00

  • Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy: results from a survey.

    abstract:BACKGROUND:The management of the large patient population in Italy receiving long-term oral anticoagulation therapy (OAT) poses organizational challenges that are traditionally approached with a centralized procedure, relying on hospital-based clinics and/or GPs. However, the availability of near-patient testing device...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11313890-000000000-00000

    authors: Pradelli L,Iannazzo S,Zaniolo O,Botrugno P

    更新日期:2010-01-01 00:00:00

  • The lifetime cost of hepatocellular carcinoma : a claims data analysis from a medical centre in Taiwan.

    abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is the second most common cancer in Taiwan. For males in Taiwan, it is the most dangerous cancer, with both the highest incidence and mortality rate. OBJECTIVE:To determine cancer-related medical care costs for long-term survivors of HCC. METHODS:The estimation of the lifetim...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200806010-00005

    authors: Lang HC,Wu JC,Yen SH,Lan CF,Wu SL

    更新日期:2008-01-01 00:00:00

  • The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience.

    abstract:BACKGROUND:There are limited economic evaluations comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for multi-vessel coronary artery disease (MVCAD) in contemporary, routine clinical practice. OBJECTIVE:The aim was to perform a cost-effectiveness analysis comparing CABG and ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0407-5

    authors: Ariyaratne TV,Ademi Z,Huq M,Rosenfeldt F,Duffy SJ,Parkinson B,Yap CH,Smith J,Billah B,Yan BP,Brennan AL,Tran L,Reid CM

    更新日期:2018-10-01 00:00:00

  • Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

    abstract::The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expen...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03256162

    authors: Sermet C,Andrieu V,Godman B,Van Ganse E,Haycox A,Reynier JP

    更新日期:2010-01-01 00:00:00

  • The influence of bonus payments to doctors on hospital revenue: results of a quasi-experimental study.

    abstract::There is wide consensus that the ways in which providers are reimbursed by third parties will affect their behaviour and, hence, the efficient use of limited resources and the performance of health systems. However, there seems to be little evidence on how payment to hospital-based doctors affects hospital performance...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:

    authors: Liu X,Mills A

    更新日期:2003-01-01 00:00:00

  • Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

    abstract:BACKGROUND:Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0050-0

    authors: Zeidler J,Mahlich J,Greiner W,Heres S

    更新日期:2013-10-01 00:00:00

  • Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

    abstract:OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-019-00496-1

    authors: Vreman RA,Geenen JW,Hövels AM,Goettsch WG,Leufkens HGM,Al MJ

    更新日期:2019-12-01 00:00:00

  • Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population.

    abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-015-0180-7

    authors: Shields GE,Bates AE,Chapman AM

    更新日期:2015-10-01 00:00:00

  • The importance of proximity to death in modelling community medication expenditures for older people: evidence from New Zealand.

    abstract:BACKGROUND:Concerns about the long-term sustainability of health care expenditures (HCEs), particularly prescribing expenditures, has become an important policy issue in most developed countries. Previous studies suggest that proximity to death (PTD) has a significant effect on total HCEs, with its exclusion leading to...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-014-0121-x

    authors: Moore PV,Bennett K,Normand C

    更新日期:2014-12-01 00:00:00

  • Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval.

    abstract:OBJECTIVE:Compared to traditional drugs, specialty drugs tend to be indicated for lower prevalence diseases. Our objective was to compare the potential population health benefits associated with specialty and traditional drugs in the year following product approval. METHODS:First, we created a dataset of estimates of ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0291-9

    authors: Chambers JD,Thorat T,Wilkinson CL,Salem M,Subedi P,Kamal-Bahl SJ,Neumann PJ

    更新日期:2017-04-01 00:00:00

  • Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.

    abstract:BACKGROUND:European guidelines advocate the measurement of on-treatment hepatitis C virus (HCV) RNA in order to determine optimal therapy duration (response-guided therapy [RGT]) in patients with rapid virological response (RVR) or delayed virological response (DVR). Treatment response is highly dependent upon the exte...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-012-0002-0

    authors: McEwan P,Kim R,Yuan Y

    更新日期:2013-02-01 00:00:00

  • Current and future economic burden of osteoporosis in New Zealand.

    abstract:BACKGROUND:Osteoporosis is recognized as a serious health condition in developed as well as developing countries. There are no accurate estimates of the extent of the burden of osteoporosis in New Zealand. The purpose of this study was to estimate the economic burden of osteoporosis in New Zealand using data from inter...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11531500-000000000-00000

    authors: Brown P,McNeill R,Leung W,Radwan E,Willingale J

    更新日期:2011-03-01 00:00:00

  • Demand for outpatient healthcare: empirical findings from rural India.

    abstract:BACKGROUND:Price, income and health status are likely to affect the demand for healthcare in developing countries, and their quantitative effects are unclear in the literature. Some studies report that prices are not important determinants, while others conclude that prices are important determinants of the demand for ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256160

    authors: Sarma S

    更新日期:2009-01-01 00:00:00